Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
StemRIM Inc. ( (JP:4599) ) has issued an update.
StemRIM Inc. has announced the upcoming registration of a medical use patent for Redasemtide, its flagship regeneration-inducing drug candidate, specifically for treating fatty liver and non-alcoholic steatohepatitis (NASH) in Japan. With no existing drug treatments for these rising lifestyle-related conditions, this move could position StemRIM as a leader in addressing unmet medical needs while bolstering its market reputation within regenerative medicine.
More about StemRIM Inc.
StemRIM Inc. is a biotechnology venture originating from Osaka University, focused on developing a novel approach called ‘Regeneration-Inducing MedicineTM.’ This method aims to achieve regenerative therapy effects by mobilizing stem cells within the body to repair and regenerate damaged tissues without using living cells or tissues. The company targets various diseases, including chronic liver disease, cardiomyopathy, spinal cord injury, and others, through its innovative therapies.
Average Trading Volume: 110,021
Technical Sentiment Signal: Sell
Current Market Cap: Yen15.86B
For a thorough assessment of 4599 stock, go to TipRanks’ Stock Analysis page.